{"prompt": "['Novartis', 'Confidential', 'Page 56', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'The study coordinator must be familiar with the instrument and the associated user guides and', 'training materials provided. Patients must complete the questionnaire in a quiet area and are', \"allowed to ask questions; however the site staff must take care not to influence the patient's\", 'response. In response to a question, patients must be instructed to provide the truest or best', 'response for them.', 'Asthma Quality of Life Questionnaire for 12 years and older (AQLQ+12)', 'In this study, the disease-specific AQLQ+12 will be used to measure health-related quality of', 'life in patients. The measure was originally validated for use in patients with asthma aged \"12', 'to 80 years (Juniper et al 2005)\".', 'The AQLQ+12 comprises a total of 32 individual questions that span a total of four domains:', 'symptoms, activity limitation, emotional function, and environmental stimuli. Test-retest', 'reliability, construct validity (cross-sectional and longitudinal), and responsiveness have been', 'demonstrated (see Appendix 8).', 'The AQLQ+12 will be self-administered at the clinic. It takes about 4 to 5 minutes to', 'complete. Patients are asked to recall their experiences during the previous 2 weeks and to', 'score each item on a 7-point scale (7 = not at all impaired to 1 = severely impaired). The', 'AQLQ+12 yields individual domain scores, which is the mean of all items in each domain,', 'and an overall score, which is the mean of all 32 individual responses. Higher scores indicate', 'less impairment in HRQOL.', 'The AQLQ+12 will be collected in an electronic format. The questionnaire will be completed', 'by patients at the visits specified in the table of assessments (See Table 6-1).', 'The appropriate language version(s) of the questionnaire will be used in each participating', 'country. The same language version of the questionnaire must be used by a particular patient', 'throughout the study.', 'The study coordinator must be familiar with the instrument and the associated user guides and', 'training materials provided. The patient must complete the questionnaire in a quiet area and', \"be allowed to ask questions; however site staff must take care not to influence the patient's\", 'responses. The patient will be instructed to provide the truest and for them best response.']['Novartis', 'Confidential', 'Page 57', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', '7', 'Safety monitoring', '7.1', 'Adverse events', 'An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and', 'unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or', 'clinical investigation subject after providing written informed consent for participation in the', 'study until the end of study visit. Therefore, an AE may or may not be temporally or causally', 'associated with the use of a medicinal (investigational) product.', 'In addition, all reports of intentional misuse and abuse of the product are also considered an', 'adverse event irrespective if a clinical event has occurred.', 'The occurrence of adverse events must be sought by non-directive questioning of the patient', 'at each visit during the study. Adverse events also may be detected when they are volunteered', 'by the patient during or between visits or through physical examination findings, laboratory', 'test findings, or other assessments.', 'Abnormal laboratory values or test results constitute adverse events only if they fulfill at least', 'one of the following criteria:', 'they induce clinical signs or symptoms,', 'they are considered clinically significant,', 'they require therapy.', 'Clinically significant abnormal laboratory values or test results must be identified through a', 'review of values outside of normal ranges/clinically notable ranges, significant changes from', 'baseline or the previous visit, or values which are considered to be non-typical in patient with', 'underlying disease. Investigators have the responsibility for managing the safety of individual', 'patient and identifying adverse events. Alert ranges for laboratory and other test abnormalities', 'are included in Appendix 1.']['Novartis', 'Confidential', 'Page 58', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or', 'diagnosis associated with them, accompanied by the following information:', 'The severity grade:', 'mild: usually transient in nature and generally not interfering with normal activities', 'moderate: sufficiently discomforting to interfere with normal activities', 'severe: prevents normal activities', 'its relationship to the study treatment', 'Yes', 'No', 'its duration (start and end dates) or if the event is ongoing an outcome of not', 'recovered/not resolved must be reported.', 'whether it constitutes a serious adverse event (SAE - See Section 7.2 for definition of SAE)', 'and which seriousness criteria have been met.', 'action taken regarding investigational treatment', 'All adverse events must be treated appropriately. Treatment may include one or more of the', 'following:', 'no action taken (e.g. further observation only)', 'investigational treatment dosage increased/reduced', 'investigational treatment interrupted/withdrawn', 'concomitant medication or non-drug therapy given', 'non-drug therapy given', \"patient hospitalized/patient's hospitalization prolonged (see Section 7.2 for definition of\", 'an SAE)', 'its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving,', 'recovered/resolved with sequelae; fatal; or unknown)', 'Once an adverse event is detected, it must be followed until its resolution or until it is judged', 'to be permanent, and assessment must be made at each visit (or more frequently, if necessary)', 'of any changes in severity, the suspected relationship to the study drug, the interventions', 'required to treat it, and the outcome.', 'Information about common side effects already known about the investigational drug can be', 'found in the investigator brochure (IB). This information will be included in the patient', 'informed consent and should be discussed with the patient during the study as needed. Any', 'new information regarding the safety profile of the medicinal product that is identified', 'between IB updates will be communicated as appropriate, for example, via an investigator', 'notification (IN) or an Aggregate Safety Finding. New information might require an update to', 'the informed consent and has then to be discussed with the patient.', 'The investigator must also instruct each patient to report any new adverse event (beyond the', \"protocol observation period) that the patient, or the patient's personal physician, believes\", 'might reasonably be related to study treatment. This information must be recorded in the']\n\n###\n\n", "completion": "END"}